Last updated on March 2019

Brentuximab for Newly Diagnosed Hodgkin Disease


Brief description of study

The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).

Clinical Study Identifier: NCT02398240

Find a site near you

Start Over

New York Medical College

Valhalla, NY United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.